Russia will launch public release of COVID-19 vaccine next month

Russia will launch public release of COVID-19 vaccine next month

Russia will start a “successful” coronavirus vaccine next month in the wake of alleged attempts by researchers in the UK, US and Canada to carry out the COVID-19 vaccine trial and steal information for use as the first vaccine. The candidate will be open to the public. To create the Holy Grail.

according to Bloomberg ReportKirill Dmitriev, CEO of the government-backed Russian Direct Investment Fund (RDIF), confirmed new developments while denying involvement in Russia’s “ridiculous” claims.

“Russia may be one of the first to produce a vaccine against the backdrop of the billions invested in the United States and all the pharmaceutical companies that work on it,” he said.

Russia could potentially produce 30 million vaccines domestically and 170 million times in the country in 2020, with five countries showing interest in producing vaccines and others eager to produce vaccines. It is target.

He further confirmed that the vaccine trial will launch Phase 3 trials on thousands of people in Russia, Saudi Arabia and the United Arab Emirates on August 3rd.

Last Sunday, Russia announced the world’s first safe and effective COVID-19 trial.

Read | Russia Develops “World’s First Successful COVID-19 Vaccine!” – Experts Say It Was Premature Celebrityate

Shortly before the announcement, the United Kingdom, Canada and the United States called on Russia for a collaborative announcement accusing them of attempting to steal information from researchers conducting COVID-19 vaccine trials.

A hacker group known as ATP29, known as part of the Russian intelligence agency, was allegedly behind the attacks on academic and pharmaceutical research institutions in three countries seeking to develop coronavirus vaccines.

However, Russia has denied all claims that the nations are facing threats, through new developments that make Russia the first superpower to manufacture a successful COVID-19 vaccine.

Russian Vaccine Candidate Based on Human Adenovirus (Common Cold Virus) Fused with Spike Protein of SARS CoV-2 to Stimulate Immune Response Funded in US, UK and Canada Competing with AstraZeneca COVID-29 vaccine Phase 3 in the UK, Brazil and South Africa.

read more